These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 12137679

  • 21. Bisphosphonates for osteoporosis in people with cystic fibrosis.
    Conwell LS, Chang AB.
    Cochrane Database Syst Rev; 2009 Oct 07; (4):CD002010. PubMed ID: 19821288
    [Abstract] [Full Text] [Related]

  • 22. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
    Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS, American Society of Clinical Oncology Bisphosphonates Expert Panel.
    J Clin Oncol; 2002 Sep 01; 20(17):3719-36. PubMed ID: 12202673
    [Abstract] [Full Text] [Related]

  • 23. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ, Mancini I.
    Support Care Cancer; 2002 Jul 01; 10(5):399-407. PubMed ID: 12136223
    [Abstract] [Full Text] [Related]

  • 24. Bisphosphonates and breast carcinoma.
    Lipton A.
    Cancer; 1997 Oct 15; 80(8 Suppl):1668-73. PubMed ID: 9362434
    [Abstract] [Full Text] [Related]

  • 25. Percutaneous vertebroplasty for osteoporotic vertebral compression fracture.
    Buchbinder R, Golmohammadi K, Johnston RV, Owen RJ, Homik J, Jones A, Dhillon SS, Kallmes DF, Lambert RG.
    Cochrane Database Syst Rev; 2015 Apr 30; (4):CD006349. PubMed ID: 25923524
    [Abstract] [Full Text] [Related]

  • 26. Anti-tumour activity of bisphosphonates in human myeloma cells.
    Shipman CM, Rogers MJ, Apperley JF, Graham R, Russell G, Croucher PI.
    Leuk Lymphoma; 1998 Dec 30; 32(1-2):129-38. PubMed ID: 10037008
    [Abstract] [Full Text] [Related]

  • 27. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
    Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD.
    N Engl J Med; 1996 Feb 22; 334(8):488-93. PubMed ID: 8559201
    [Abstract] [Full Text] [Related]

  • 28. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
    Cranney A, Waldegger L, Zytaruk N, Shea B, Weaver B, Papaioannou A, Robinson V, Wells G, Tugwell P, Adachi JD, Guyatt G.
    Cochrane Database Syst Rev; 2003 Feb 22; (4):CD004523. PubMed ID: 14584020
    [Abstract] [Full Text] [Related]

  • 29. Conservative interventions for treating middle third clavicle fractures in adolescents and adults.
    Lenza M, Faloppa F.
    Cochrane Database Syst Rev; 2016 Dec 15; 12(12):CD007121. PubMed ID: 27977849
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Bisphosphonates in multiple myeloma.
    Berenson JR.
    Cancer; 1997 Oct 15; 80(8 Suppl):1661-7. PubMed ID: 9362433
    [Abstract] [Full Text] [Related]

  • 32. Interventions for preventing bone disease in kidney transplant recipients.
    Palmer S, McGregor DO, Strippoli GF.
    Cochrane Database Syst Rev; 2005 Apr 18; (2):CD005015. PubMed ID: 15846740
    [Abstract] [Full Text] [Related]

  • 33. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.
    Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedenus M, Ford J, Kandra A.
    Br J Haematol; 1998 May 18; 101(2):280-6. PubMed ID: 9609523
    [Abstract] [Full Text] [Related]

  • 34. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M, Pogłód R, Maj S, Pawlikowski J, Sokołowska U, Szczepanik J.
    Acta Pol Pharm; 2002 May 18; 59(6):478-82. PubMed ID: 12669777
    [Abstract] [Full Text] [Related]

  • 35.
    Kongsgaard U, Kaasa S, Dale O, Ottesen S, Nordøy T, Hessling SE, von Hofacker S, Bruland ØS, Lyngstadaas A.
    ; 2005 12 18. PubMed ID: 29320015
    [Abstract] [Full Text] [Related]

  • 36. Bisphosphonate therapy in multiple myeloma.
    Laakso M, Jantunen E.
    Acta Oncol; 1996 12 18; 35 Suppl 5():55-6. PubMed ID: 9142966
    [Abstract] [Full Text] [Related]

  • 37. Bisphosphonates in multiple myeloma.
    Apperley JF, Croucher PI.
    Pathol Biol (Paris); 1999 Feb 18; 47(2):178-81. PubMed ID: 10192885
    [Abstract] [Full Text] [Related]

  • 38. Treatment of painful bone lesions and hypercalcemia.
    Ascari E, Attardo-Parrinello G, Merlini G.
    Eur J Haematol Suppl; 1989 Feb 18; 51():135-9. PubMed ID: 2534078
    [Abstract] [Full Text] [Related]

  • 39. Therapeutic options in the management of myeloma bone disease.
    Berenson JR.
    Semin Oncol; 2010 Jun 18; 37 Suppl 1():S20-9. PubMed ID: 20682368
    [Abstract] [Full Text] [Related]

  • 40. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
    Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, García-Sanz R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, Spencer A, Leleu X, Cavo M, Munshi N, Rajkumar SV, Durie BG, Roodman GD.
    J Clin Oncol; 2013 Jun 20; 31(18):2347-57. PubMed ID: 23690408
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.